Shots:

• Enterome to get $50M upfront plus $640M as milestones payments and future equity investment commitment from Takeda. The companies will jointly co-develop EB8018 and if approved- the product will be co-promoted in the US with equal profit/cost sharing
• Takeda to get hold of exclusive license rights for EB8018 to commercialize outside the US and give royalties on sales to Enterome
• EB8018 PO is a novel P-Ib candidate indicated in Crohn’s disease- testing its safety- tolerability- PK & efficacy and has successfully completed its P-Ia

  Ref: Enterome Biosciences | Image: Takeda